


Otamixaban

Chemical Properties

CAS No.:	193153-04-7
Formula:	C ₂₅ H ₂₆ N ₄ O ₄
Molecular Weight:	446.5
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

Description	Otamixaban(FXV673) is an effective ($K_i = 0.5$ nM), selective, rapid-acting, competitive, and reversible fXa inhibitor. It also effectively inhibits both free and prothrombinase-bound fXa.
Targets(IC ₅₀)	Others: None
In vivo	Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis showed in vivo experiments. Recent clinical findings indicate that Otamixaban is efficacious, safe, and well-tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome.

Solubility Information

Solubility	DMSO: 50 mg/mL (111.98 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.24 mL	11.198 mL	22.396 mL
5 mM	0.448 mL	2.24 mL	4.479 mL
10 mM	0.224 mL	1.12 mL	2.24 mL
50 mM	0.045 mL	0.224 mL	0.448 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Eikelboom JW, Weitz JI. Otamixaban in acute coronary syndromes. *Lancet*. 2009 Sep 5;374(9692):762-4. Epub 2009 Aug 28.
2. Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. *Lancet*. 2009 Sep 5;374(9692):787-95. Epub 2009 Aug 28
3. Guertin KR, Choi YM. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. *Curr Med Chem*. 2007;14(23):2471-81.
4. Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. *Circulation*. 2007
5. Guertin, Kevin R.; Choi, Yong-Mi. The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development. *Current Medicinal Chemistry* (2007), 14(23), 2471-2481.

[Inhibitors](#) · [Natural Compounds](#) · [Compound Libraries](#)

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel: 781-999-4286

E-mail: info@targetmol.com

Address: 36 Washington Street, Wellesley Hills, MA 02481